Volv Global set on expansion course

"Our growth is a reflection of our mission—to provide new knowledge at speed, enabling us to do more with less," said Christopher Rudolf, CEO of Volv Global. "As we scale, our new space will serve as a hub for collaboration, where our multidisciplinary teams can push the boundaries of AI-driven discovery in healthcare."

Over the past year, Volv Global has significantly expanded its team, attracting top talent across data science, machine learning, and healthcare. This move not only meets the immediate need for additional space but also strengthens the company’s ability to drive impact—enhancing pharmaceutical R&D strategies, optimizing clinical pathways, and personalizing patient care.

On the commercial front, the company explains to Startupticker.ch that it has expanded its presence in Germany since the beginning of 2025 and developed major new capabilities for key customers that will be rolled out extensively. With an increase in turnover compared to last year, the company is confident thanks to a solid portfolio of clients and projects for 2025 and beyond, with bookings up to four years in advance.

Volv Global delivers patient and disease insights to support strategy development and planning for pharmaceutical companies throughout clinical development, HEOR, medical affairs and commercial activities. Volv’s Marketing Director Le Vin Chin tells us more: “With a focus on difficult-to-diagnose diseases, we can find patients which are undiagnosed or misdiagnosed, find them before development of traditional symptoms, predict disease outcomes and differentiate subgroups of patients. Our custom and proprietary machine learning algorithms power a suite of services that reduces costs throughout the healthcare ecosystem and improves outcomes for those living with disease.”

Working on the Future of AI-Driven Healthcare

With a multinational team spanning Europe and the U.S., Volv Global remains focused on its core mission: to speed science, reduce the cost of healthcare, close the diagnostic gap, and improve outcomes for people living with disease. The expanded office space enables the company to advance this vision—supporting pharmaceutical partners with unparalleled data intelligence and transforming the future of patient care.

The proprietary process and methodology of Volv’s machine learning algorithm is under continuous improvement. While the team is working full force on delivery of current projects, it is also working towards its vision of providing new knowledge at speed to connect patients to the treatment they need. Speaking of the company's future plans, Volv’s Marketing Director Le Vin Chin adds “We are interested in strategic partnerships. As a self-funded company we have always been in revenue. We are also interested in exploring both non-dilutive funding as well as strategic growth partners.”

(PR - ES)